Jan Traub
YOU?
Author Swipe
View article: High interleukin-8 serum levels independently predict long-term all-cause mortality in chronic heart failure
High interleukin-8 serum levels independently predict long-term all-cause mortality in chronic heart failure Open
Background Chronic heart failure (HF) is a complex syndrome with significant morbidity and mortality, where inflammation is increasingly recognized as a critical factor in its progression. This study investigated the association of cytokin…
View article: High interleukin-8 serum levels independently predict long-term all-cause mortality in chronic heart failure
High interleukin-8 serum levels independently predict long-term all-cause mortality in chronic heart failure Open
Background Chronic heart failure (HF) is a complex syndrome with significant morbidity and mortality, where inflammation is increasingly recognized as a critical factor in its progression. This study investigated the association of cytokin…
View article: Plasma levels of sTREM2 in chronic heart failure: predictors and prognostic relevance
Plasma levels of sTREM2 in chronic heart failure: predictors and prognostic relevance Open
This study establishes a significant association between elevated plasma sTREM2 levels and cognitive impairment in chronic patients with heart failure (HF), particularly in working memory and attention. Although higher sTREM2 levels correl…
View article: S100B Serum Levels in Chronic Heart Failure Patients: A Multifaceted Biomarker Linking Cardiac and Cognitive Dysfunction
S100B Serum Levels in Chronic Heart Failure Patients: A Multifaceted Biomarker Linking Cardiac and Cognitive Dysfunction Open
S100 calcium-binding protein B (S100B) is a protein primarily known as a biomarker for central nervous system (CNS) injuries, reflecting blood–brain barrier (BBB) permeability and dysfunction. Recently, S100B has also been implicated in ca…
View article: Long‐term cognitive and brain morphologic changes in chronic heart failure: Results of the Cognition.Matters‐HF study
Long‐term cognitive and brain morphologic changes in chronic heart failure: Results of the Cognition.Matters‐HF study Open
Aims Cognitive impairment (CI) is a common, yet frequently unrecognized co‐morbidity in chronic heart failure (HF). We quantified trajectories of cognitive performance, brain volume, and related clinical outcome over a time course of 6 yea…
View article: Differential Role of Factor XIII in Acute Myocardial Infarction and Ischemic Stroke
Differential Role of Factor XIII in Acute Myocardial Infarction and Ischemic Stroke Open
Factor XIII is a transglutaminase enzyme that plays a crucial role in hemostasis and wound healing. It crosslinks fibrin strands, stabilizing clots and promoting clot resistance to fibrinolysis. Additionally, Factor XIII has been found to …
View article: Impact of Radiotherapy on Malfunctions and Battery Life of Cardiac Implantable Electronic Devices in Cancer Patients
Impact of Radiotherapy on Malfunctions and Battery Life of Cardiac Implantable Electronic Devices in Cancer Patients Open
Purpose: This study analyses a large number of cancer patients with CIEDs for device malfunction and premature battery depletion by device interrogation after each radiotherapy fraction and compares different guidelines in regard to patien…
View article: Internal carotid artery blood flow and pulsatility index in cognitively impaired people with chronic heart failure
Internal carotid artery blood flow and pulsatility index in cognitively impaired people with chronic heart failure Open
Aims Mild cognitive impairment and dementia are common and serious co‐morbidities in people with chronic heart failure (HF) as they increase hospitalization rates, mortality and health care costs. Upon other factors, dysregulated cerebral …
View article: Profiles of cognitive impairment in chronic heart failure—A cluster analytic approach
Profiles of cognitive impairment in chronic heart failure—A cluster analytic approach Open
Background Cognitive impairment is a major comorbidity in patients with chronic heart failure (HF) with a wide range of phenotypes. In this study, we aimed to identify and compare different clusters of cognitive deficits. Methods The prosp…
View article: Chronic Neuroinflammation and Cognitive Decline in Patients with Cardiac Disease: Evidence, Relevance, and Therapeutic Implications
Chronic Neuroinflammation and Cognitive Decline in Patients with Cardiac Disease: Evidence, Relevance, and Therapeutic Implications Open
Acute and chronic cardiac disorders predispose to alterations in cognitive performance, ranging from mild cognitive impairment to overt dementia. Although this association is well-established, the factors inducing and accelerating cognitiv…
View article: Features of metabolic syndrome and inflammation independently affect left ventricular function early after first myocardial infarction
Features of metabolic syndrome and inflammation independently affect left ventricular function early after first myocardial infarction Open
Both BMI and HbA1c correlated negatively with LVEF only early, but not late after STEMI. Peak CRP evolved as strongest predictor of cardiac function at all time points independent of the metabolic syndrome.
View article: Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients
Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients Open
Background Chronic heart failure (HF) is known to increase the risk of developing Alzheimer’s dementia significantly. Thus, detecting and preventing mild cognitive impairment, which is common in patients with HF, is of great importance. Se…
View article: Sustained Increase in Serum Glial Fibrillary Acidic Protein after First ST-Elevation Myocardial Infarction
Sustained Increase in Serum Glial Fibrillary Acidic Protein after First ST-Elevation Myocardial Infarction Open
Acute ischemic cardiac injury predisposes one to cognitive impairment, dementia, and depression. Pathophysiologically, recent positron emission tomography data suggest astroglial activation after experimental myocardial infarction (MI). We…
View article: Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure
Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure Open
Aims Cognitive dysfunction occurs frequently in patients with heart failure (HF), but early detection remains challenging. Serum glial fibrillary acidic protein (GFAP) is an emerging biomarker of cognitive decline in disorders of primary n…
View article: B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders
B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders Open
The first description of neuromyelitis optica by Eugène Devic and Fernand Gault dates back to the 19th century, but only the discovery of aquaporin-4 autoantibodies in a major subset of affected patients in 2004 led to a fundamentally revi…
View article: The effect of dimethyl fumarate on phenotype and function of B lymphocytes in MS patients
The effect of dimethyl fumarate on phenotype and function of B lymphocytes in MS patients Open
Although the oral agent DMF was approved for the treatment of RRMS in 2014 and demonstrably reduces relapse rates and disability progression, its effect on B cells, which are now thought to be major contributors to disease activity, remain…
View article: Differential Effects of MS Therapeutics on B Cells—Implications for Their Use and Failure in AQP4-Positive NMOSD Patients
Differential Effects of MS Therapeutics on B Cells—Implications for Their Use and Failure in AQP4-Positive NMOSD Patients Open
B cells are considered major contributors to multiple sclerosis (MS) pathophysiology. While lately approved disease-modifying drugs like ocrelizumab deplete B cells directly, most MS medications were not primarily designed to target B cell…
View article: Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS
Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS Open
GA immune modulates B-cell function in EAE and MS and efficiently interferes with pathogenic B cell-T cell interaction.
View article: Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients
Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients Open
Background In the past, multiple sclerosis (MS) medications have been primarily designed to modulate T cell properties. Based on the emerging concept that B cells are equally important for the propagation of MS, we compared the effect of f…
View article: Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis
Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis Open
In multiple sclerosis (MS), the effect of dimethyl fumarate (DMF) treatment is primarily attributed to its capacity to dampen pathogenic T cells. Here, we tested whether DMF also modulates B cells, which are newly recognized key players in…